PHASE II STUDY OF CELECOXIB AND DOCETAXEL IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH PROGRESSION AFTER PLATINUM-BASED THERAPY

INTRODUCTION: To evaluate the efficacy and toxicity of the combination of celecoxib and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) after failure of platinum-based therapy. METHODS: Patients with relapsed NSCLC received celecoxib 400 mg orally twice daily beginning 7 days...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Schneider, Bryan J., Kalemkerian, Gregory P., Kraut, Michael J., Wozniak, Antoinette J., Worden, Francis P., Smith, Daryn W., Chen, Wei, Gadgeel, Shirish M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3771331/
https://ncbi.nlm.nih.gov/pubmed/19057272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31818de1d2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados